ClinicalTrials.gg
CompletedNCT02006667Updated Feb 11, 2015Results posted

A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer

A Phase 2 interventional study of trastuzumab and gemcitabine in Urinary Tract Cancer, sponsored by Hoffmann-La Roche. Completed at 7 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-02-11.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
13
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies in Urologic Neoplasms with a site in Germany — 2 open to participants now, 3 under way, none of them phase 3. Urologic Neoplasms · Germany.

Enrollment
9th of 10
13 · median 200
Started
2001
with 1 other
Phase 2
7 of 13
1 open now
Registered
5th of 13
by date
Lead sponsor
3 of 13
Hoffmann-La Roche

Among the 13 studies in Urologic Neoplasms with a site in Germany, this one is the 9th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2001, is one of 7 in phase 2, and was the 5th registered.

Urologic Neoplasms

155 studies on the registry are indexed under Urologic Neoplasms; 40 are open to participants now.

Browse Urologic Neoplasms studies →

Open to participants now

2 of the 13 studies in Urologic Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 30 Urologic Neoplasms studies recruiting now, 24 (80%) set no upper age limit and 2 (7%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Urologic Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of a chemotherapy regimen of intravenous Herceptin, cisplatin and gemcitabine in patients with metastatic urothelial cancer. The anticipated time on study treatment is until disease progression.

03

Conditions studied

  • Urinary Tract Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients with >=18 years of age;
  • urothelial carcinoma;
  • measurable metastases or local recurrent disease;
  • no prior chemotherapy for metastatic disease;
  • overexpression (IHC [2+] or [3+]).

Exclusion criteria

Exclusion Criteria:

  • concomitant chemotherapy or immunotherapy;
  • active or uncontrolled infection;
  • solely ;
  • cardiac disease, advanced pulmonary disease or severe dyspnoea;
  • co-existing diagnosed within last 5 years, except basal cell cancer or cervical cancer in situ.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Trastuzumab, Gemcitabine, Cisplatin

    Participants received an initial loading dose of 4 milligrams per kilogram (mg/kg) trastuzumab intravenous (i.v.) on Day 3 of Cycle 1, followed by weekly doses of 2 mg/kg i.v until disease progression; 1200 mg per square meter (m2) gemcitabine i.v. on Days 1, 8, and 15 of Cycles 1 through 6; and 70 mg/m2 cisplatin i.v. on Day 2 of Cycles 1 through 6.

    Drug: trastuzumab · Drug: gemcitabine · Drug: cisplatin

Interventions

  • 4 mg/kg i.v., Day 3 of Cycle 1, followed by weekly doses of 2 mg/kg i.v., Day 1 of Cycle 2 until disease progression

    Also known as: Herceptin

  • 1200 mg/m2 i.v. on Days 1, 8, and 15 of Cycle 1 through 6

  • 70 mg/m2 i.v. on Day 2 of Cycles 1 through 6

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) - Percentage of Participants With an Event

    PFS was defined as the time from the first dose of study treatment to the first documentation of objective tumor progression or death due to any cause.

    Time frame: Screening, Day 1 of Cycles 1 through 6, every 4 weeks until end of treatment, up to 33 months

  2. Progression-Free Survival - Time to Event

    The median time, in months, from the first dose of study treatment to PFS event.

    Time frame: Screening, Day 1 of Cycles 1 through 6, every 4 weeks until end of treatment, up to 33 months

  3. Percentage of Participants Who Were Progression Free at 12 and 24 Months

    Time frame: Screening, and Months 12 and 24

Secondary outcomes

  1. Overall Survival (OS) - Percentage of Participants With an Event

    OS was defined as the time from the start of study treatment to date of death due to any cause.

    Time frame: Screening, Day 1 of Cycles 1 through 6, every 4 weeks until end of treatment, up to 36 months

  2. Overall Survival - Time to Event

    The median time, in months, from the start of study treatment to OS event.

    Time frame: Screening, Day 1 of Cycles 1 through 6, every 4 weeks until end of treatment, up to 36 months

  3. Percentage of Participants Surviving at 12 and 24 Months

    Time frame: Screening, and Months 12 and 24

  4. Percentage of Participants Achieving Complete Response (CR), Partial Response (PR), or Stable Disease (SD)

    Per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1): CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal \[(short axis less than (\<) 10 millimeters (mm)\]. No new lesions. PR was defined as greater than or equal to (≥) 30 percent (%) decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. SD was defined as not qualifying for CR, PR, or Progressive Disease (PD).

    Time frame: Screening, Day 1 of Cycles 1 through 6, every 4 weeks until end of treatment, up to 33 months

07

Results

Posted Feb 11, 2015

Participant flow

Participant flow — Overall Study
MilestoneTrastuzumab/Gemcitabine/Cisplatin
Started13
Completed7
Not completed6
Withdrew: Adverse event3
Withdrew: Death2
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryProgression-Free Survival (PFS) - Percentage of Participants With an Event

PFS was defined as the time from the first dose of study treatment to the first documentation of objective tumor progression or death due to any cause.

Time frame:
Screening, Day 1 of Cycles 1 through 6, every 4 weeks until end of treatment, up to 33 months
Reported as:
Number · percentage of participants
Progression-Free Survival (PFS) - Percentage of Participants With an Event
percentage of participantsTrastuzumab/Gemcitabine/Cisplatin
Progression-Free Survival (PFS) - Percentage of Participants With an Event92.3
PrimaryProgression-Free Survival - Time to Event

The median time, in months, from the first dose of study treatment to PFS event.

Time frame:
Screening, Day 1 of Cycles 1 through 6, every 4 weeks until end of treatment, up to 33 months
Reported as:
Median · months
Progression-Free Survival - Time to Event
monthsTrastuzumab/Gemcitabine/Cisplatin
Progression-Free Survival - Time to Event11.0 (5.7 to 14.3)
PrimaryPercentage of Participants Who Were Progression Free at 12 and 24 Months
Time frame:
Screening, and Months 12 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Progression Free at 12 and 24 Months
percentage of participantsTrastuzumab/Gemcitabine/Cisplatin
12 Months38.5 (14.1 to 62.8)
24 Months15.4 (2.5 to 38.8)
SecondaryOverall Survival (OS) - Percentage of Participants With an Event

OS was defined as the time from the start of study treatment to date of death due to any cause.

Time frame:
Screening, Day 1 of Cycles 1 through 6, every 4 weeks until end of treatment, up to 36 months
Reported as:
Number · percentage of participants
Overall Survival (OS) - Percentage of Participants With an Event
percentage of participantsTrastuzumab/Gemcitabine/Cisplatin
Overall Survival (OS) - Percentage of Participants With an Event84.6
SecondaryOverall Survival - Time to Event

The median time, in months, from the start of study treatment to OS event.

Time frame:
Screening, Day 1 of Cycles 1 through 6, every 4 weeks until end of treatment, up to 36 months
Reported as:
Median · months
Overall Survival - Time to Event
monthsTrastuzumab/Gemcitabine/Cisplatin
Overall Survival - Time to Event14.9 (12.9 to 21.7)
SecondaryPercentage of Participants Surviving at 12 and 24 Months
Time frame:
Screening, and Months 12 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Surviving at 12 and 24 Months
percentage of participantsTrastuzumab/Gemcitabine/Cisplatin
12 Months76.9 (44.2 to 91.9)
24 Months23.1 (5.6 to 47.5)
SecondaryPercentage of Participants Achieving Complete Response (CR), Partial Response (PR), or Stable Disease (SD)

Per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1): CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal \[(short axis less than (\<) 10 millimeters (mm)\]. No new lesions. PR was defined as greater than or equal to (≥) 30 percent (%) decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. SD was defined as not qualifying for CR, PR, or Progressive Disease (PD).

Time frame:
Screening, Day 1 of Cycles 1 through 6, every 4 weeks until end of treatment, up to 33 months
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Complete Response (CR), Partial Response (PR), or Stable Disease (SD)
percentage of participantsTrastuzumab/Gemcitabine/Cisplatin
CR15.4
PR23.1
SD46.2
PD15.4
CR/PR38.5
CR/PR/SD84.6

Adverse events

Collected over Adverse events were reported from randomization until 30 days after the end of treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trastuzumab/Gemcitabine/Cisplatin—8/13 (61.5%)9/13 (69.2%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventTrastuzumab/Gemcitabine/Cisplatin
Platelet count decreasedInvestigations2/13
TachyarrhythmiaCardiac disorders1/13
Gastrointestinal hermorrhageGastrointestinal disorders1/13
IleusGastrointestinal disorders1/13
ChillGeneral disorders1/13
FatigueGeneral disorders1/13
FeverGeneral disorders1/13
General disorders-otherGeneral disorders1/13
Catheter related infectionInfections and infestations1/13
White blood cell decreasedInvestigations1/13
Most frequent other events
Showing 10 of 44
Most frequent other events
EventTrastuzumab/Gemcitabine/Cisplatin
Platelet count decreasedInvestigations6/13
NauseaGastrointestinal disorders5/13
VomitingGastrointestinal disorders3/13
ChillsGeneral disorders3/13
FatigueGeneral disorders3/13
White blood cell decreasedInvestigations3/13
DyspneaRespiratory, thoracic and mediastinal disorders3/13
AnemiaBlood and lymphatic system disorders2/13
Urinary tract infectionInfections and infestations2/13
Creatinine increasedInvestigations2/13

Baseline characteristics

Full analysis set (FAS) included all enrolled participants who received study treatment.

Age, Continuous
Age, Continuous(years)Trastuzumab/Gemcitabine/Cisplatin
Mean68.4 ± 8.0
Sex: Female, Male
Sex: Female, Male(Participants)Trastuzumab/Gemcitabine/Cisplatin
Female3
Male10
08

Study locations

7 sites
  • Aschersleben, 06449, Germany
  • Dessau, 06846, Germany
  • Fulda, 36043, Germany
  • Leipzig, 04103, Germany
  • Leipzig, 04277, Germany
  • Marburg, 35043, Germany
  • Weiden, 92637, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2001, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2015, 5 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2013
First posted
Dec 10, 2013
Start
Jan 2001
Primary completionActual
Jan 2010
CompletionActual
Jan 2010
Results first posted
Feb 11, 2015
Last update
Feb 11, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02006667
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 10, 2013
Start date
Jan 2001
Primary completion
Jan 2010
Completion
Jan 2010
Results posted
Feb 11, 2015
Last update
Feb 11, 2015

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trastuzumab · Gemcitabine · Cisplatin

Start the discussion